tislelizumab,ociperlimab
beigene,arcus biosciences,roche,gilead,novartis,iteos therapeutics
['advantig,105', 'gastric', '$bgne', '$itos', '$rcus', '$rhhby', '$gild']
$bgne tigit + pd-1 in advantig-105: 58% orr in gastric adeno (arguably irrespective of pd-l1 expression), but 50% serious tox seems high. via se hyun kim #asco23 $rhhby $gild $rcus $itos 
Once had a blue tick. Journalist at Evaluate Vantage. Interested in: oncology, immunology. Not interested in: what stock you bought today.